Paricalcitol

• CAT Number: I001229
• CAS Number: 131918-61-1
• Molecular Formula: C27H44O3
• Molecular Weight: 416.6
• Purity: ≥95%
• Target: VD/VDR
• Solubility: 10 mM in water
• Storage: Store at -20°C
• IUPAC Name: (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
• InChI: InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
• InChIKey: BPKAHTKRCLCHEA-UBFJEZKGSA-N
• SMILES: O[C@@H](C[C@H](O)C/1)CC1=CC=C2CCC[C@@]3(C)[C@@]/2([H])CC[C@]3([H])[C@H](C)/C=C/[C@H](C)C(C)(O)C

Paricalcitol (Cat.No:I001229) is a synthetic vitamin D analogue used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. It acts as an agonist of the vitamin D receptor, regulating calcium and phosphate metabolism. Paricalcitol helps to reduce elevated parathyroid hormone levels, promoting bone health and mineral balance in patients with renal dysfunction.

Reference

1:Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway. Hong YA, Yang KJ, Jung SY, Park KC, Choi H, Oh JM, Lee SJ, Chang YK, Park CW, Yang CW, Kim SY, Hwang HS.Oxid Med Cell Longev. 2017;2017:5031926. doi: 10.1155/2017/5031926. Epub 2017 Mar 29. PMID: 28465762 Free PMC Article2:Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. Freundlich M, Abitbol CL.Pediatr Nephrol. 2017 Apr 27. doi: 10.1007/s00467-017-3675-7. [Epub ahead of print] PMID: 28451892 3:Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. Pihlstrøm HK, Gatti F, Hammarström C, Eide IA, Kasprzycka M, Wang J, Haraldsen G, Svensson MHS, Midtvedt K, Mjøen G, Dahle DO, Hartmann A, Holdaas H.Transpl Int. 2017 Apr 24. doi: 10.1111/tri.12973. [Epub ahead of print] PMID: 28436117 4:Improved regeneration and de novo bone formation in a diabetic zebrafish model treated with paricalcitol and cinacalcet. Carvalho FR, Fernandes AR, Cancela ML, Gavaia PJ.Wound Repair Regen. 2017 Apr 5. doi: 10.1111/wrr.12536. [Epub ahead of print] PMID: 28380670 5:Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Webb NJ, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB.Pediatr Nephrol. 2017 Mar 22. doi: 10.1007/s00467-017-3579-6. [Epub ahead of print] PMID: 28332096 6:The vitamin D analogue paricalcitol attenuates hepatic ischemia/reperfusion injury through down-regulation of Toll-like receptor 4 signaling in rats. Kim MS, Lee S, Jung N, Lee K, Choi J, Kim SH, Jun J, Lee WM, Chang Y, Kim D.Arch Med Sci. 2017 Mar 1;13(2):459-469. doi: 10.5114/aoms.2016.60650. Epub 2016 Jun 17. PMID: 28261302 Free PMC Article7:[Paricalcitol – a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease]. Matuszkiewicz-Rowińska J, Żebrowski P.Wiad Lek. 2016;69(5):756-759. Polish. PMID: 28033603 8:Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC.Nutrients. 2016 Nov 5;8(11). pii: E708. PMID: 27827962 Free PMC Article9:Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. Fujii H, Yonekura Y, Nakai K, Kono K, Goto S, Nishi S.J Steroid Biochem Mol Biol. 2017 Mar;167:55-60. doi: 10.1016/j.jsbmb.2016.11.002. Epub 2016 Nov 3. PMID: 27818277 10:Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. Donate-Correa J, Henríquez-Palop F, Martín-Núñez E, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.Transplantation. 2016 Nov;100(11):2432-2438. PMID: 27467536